Download PDF
Synlett 2018; 29(04): 477-482
DOI: 10.1055/s-0036-1591725
letter
© Georg Thieme Verlag Stuttgart · New York

2-Phenyl-2,3-dihydrobenzo[d]thiazole: A Mild, Efficient, and Highly Active in situ Generated Chemoselective Reducing Agent for the One-Pot Synthesis of 5-Monoalkylbarbiturates in Water

Subarna Jyoti Kalita
Department of Chemistry, University of Gauhati, G. B. Nagar, Guwahati 781014, Assam, India   Email: dcdeka@rediffmail.com
,
Dibakar Chandra Deka*
Department of Chemistry, University of Gauhati, G. B. Nagar, Guwahati 781014, Assam, India   Email: dcdeka@rediffmail.com
› Author Affiliations
Further Information

Publication History

Received: 15 October 2017

Accepted: 24 October 2017

Publication Date:
28 November 2017 (online)

    Permissions and Reprints All articles of this category


Abstract

A metal- and catalyst-free reductive alkylation protocol for the one-pot synthesis of 5-monoalkylbarbiturates from barbituric acids and aldehydes using the in situ generated chemoselective reducing agent 2-phenyl-2,3-dihydrobenzo[d]thiazole from 2-aminothiophenol and benzaldehyde is described. The notable advantages of the protocol are operational simplicity, mild reaction conditions, high yield, short reaction time, and simple workup and purification process which make it highly attractive.

Key words

5-monoalkylbarbiturates - benzothiazoline - transfer hydrogenation - aqueous media - metal- and catalyst-free

Supporting Information

    Supporting information for this article is available online at https://doi.org/10.1055/s-0036-1591725.
  • Supporting Information
 

  • References and Notes

    • 1a Shonle H. Moment A. J. Am. Chem. Soc. 1923; 45: 243
      Crossref
    • 1b Nielsen C. Higgins JA. Spruth HC. J. Pharmacol. Exp. Ther. 1925; 26: 371
    • 2a Kliethermes CL. Metten P. Belknap JK. Buck KJ. Crabbe JC. Brain Res. 2004; 1009: 17
      CrossrefPubMed
    • 2b Morgan WW. Adv. Alcohol Subst. Abuse 1990; 9: 67
      CrossrefPubMed
  • 3 Ashour OM. Naguib FN. Khalifa MM. AbdelRaheem MH. Panzica RP. el Kouni MH. Cancer Res. 1995; 55: 1092
    PubMed
    • 4a Andrews PR. Jones GP. Lodge D. Eur. J. Pharmacol. 1979; 55: 115
      CrossrefPubMed
    • 4b Mcdonald RL. Barker JL. Neurology 1979; 4: 432
    • 4c Andrews PR. Jones GP. Poulton DB. Eur. J. Pharmacol. 1982; 79: 61
      CrossrefPubMed
    • 4d Andrews PR. Mark LC. Winkler DA. Jones GP. J. Med. Chem. 1983; 26: 1223
      CrossrefPubMed
    • 4e Archana Srivastava VK. Kumar A. Bioorg. Med. Chem. 2004; 12: 1257
      CrossrefPubMed
  • 5 Gomez GG. Hutchison RB. Kruse CA. Cancer Treat. Rev. 2001; 27: 375
    CrossrefPubMed
    • 6a Glover A. Chun HG. Kleinman LM. Cooney DA. Plowman J. Grieshaber CK. Malspeis L. Leyland-Jones B. Invest. New Drugs 1987; 5: 137
      PubMed
    • 6b Ziarani GM. Alealia F. Lashgari N. RSC Adv. 2016; 6: 50895
      Crossref
    • 7a Miller AA. Bundy GL. Mott JE. Skepner JE. Boyle TP. Harris DW. Hromockyj AE. Marotti KR. Zurenko GE. Munzner JB. Sweeney MT. Bammert GF. Hamel JC. Ford CW. Zhong W.-Z. Graber DR. Martin GE. Han F. Dolak LA. Seest EP. Ruble JC. Kamilar GM. Palmer JR. Banitt LS. Hurd AR. Barbachyn MR. Antimicrob. Agents Chemother. 2008; 52: 2806
      CrossrefPubMed
    • 7b Ruble JC. Hurd AR. Johnson TA. Sherry DA. Barbachyn MR. Toogood PL. Bundy GL. Graber DR. Kamilar GM. J. Am. Chem. Soc. 2009; 131: 3991
      CrossrefPubMed
    • 8a Brandstetter H. Grams F. Glitz D. Lang A. Huber R. Bode W. Krell H.-W. Engh RA. J. Biol. Chem. 2001; 276: 17405
      CrossrefPubMed
    • 8b Fisher JF. Mobashery S. Cancer Metastasis Rev. 2006; 25: 115
      CrossrefPubMed
    • 8c Fridman R. Cancer Metastasis Rev. 2006; 25: 7
      Crossref
    • 8d Faust A. Waschkau B. Waldeck J. Höltke C. Breyholz H.-J. Wagner S. Kopka K. Heindel W. Schäfers M. Bremer C. Bioconjugate Chem. 2008; 19: 1001
      CrossrefPubMed
    • 8e Wang J. O'Sullivan S. Harmon S. Keaveny R. Radomski MW. Medina C. Gilmer JF. J. Med. Chem. 2012; 55: 2154
      CrossrefPubMed
  • 9 Xia G. Benmohamed R. Kim J. Arvanites AC. Morimoto RI. Ferrante RJ. Kirsch DR. Silverman RB. J. Med. Chem. 2011; 54: 2409
    CrossrefPubMed
  • 10 Calamai E. Dall’Angelo S. Koss D. Domarkas J. McCarthy TJ. Mingarelli M. Riedel G. Schweiger LF. Welch A. Platt B. Zanda M. Chem. Commun. 2013; 792
    • 11a Bartzatt RJ. J. Pharm. Biomed. Anal. 2002; 29: 909
      CrossrefPubMed
    • 11b Lee H. Berezin MY. Gou K. Kao J. Achilefu S. Org. Lett. 2009; 11: 29
      CrossrefPubMed
    • 12a Ivanova BB. Spitellar M. Cryst. Growth Des. 2010; 10: 2470
      Crossref
    • 12b Andreu R. Garín J. Orduna J. Alcalá R. Villacampa B. Org. Lett. 2003; 5: 3143
      CrossrefPubMed
    • 13a Prins LJ. Jolliffe KA. Hulst R. Timmerman P. Reinhoudt DN. J. Am. Chem. Soc. 2000; 122: 3617
      Crossref
    • 13b Timmerman P. Prins LJ. Eur. J. Org. Chem. 2001; 3191
    • 13c McClenaghan ND. Absalon C. Bassani DM. J. Am. Chem. Soc. 2003; 125: 13004
      CrossrefPubMed
    • 13d Yagai S. Karatsu T. Kitamura A. Langmuir 2005; 21: 11048
      CrossrefPubMed
    • 14a Devi I. Bhuyan PJ. Tetrahedron Lett. 2005; 46: 5727
      Crossref
    • 14b Weygand–Hilgetag Preparative Organic Chemistry . Hilgetag G. Martini A. Wiley; New York: 1972: 493
      Google Scholar
    • 15a Zalukaev LP. Trostyanetskaya VL. Chem. Heterocycl. Compd. 1971; 7: 781; Khim. Geterotsikl. Soedin. 1971, 6, 836
      Crossref
    • 15b Volonterio A. Zanda M. Org. Lett. 2007; 9: 841
      CrossrefPubMed
  • 16 Jursic BS. Neumann DM. Tetrahedron Lett. 2001; 42: 4103
    Crossref
  • 17 Jursic BS. Stevens ED. Tetrahedron Lett. 2003; 44: 2203
    Crossref
  • 18 Denmark SE. Ibrahim MY. S. Ambrosi A. ACS Catal. 2017; 7: 613
    Crossref
    • 19a Cui H. Ruda GF. Carrero-Lérida J. Ruiz-Pérez a LM. Gilbert IH. González-Pacanowska D. Eur. J. Med. Chem. 2010; 45: 5140
      CrossrefPubMed
    • 19b Vieira AA. Gomes NM. Matheus ME. Fernandes PD. Figueroa-Villar JD. J. Braz. Chem. Soc. 2011; 22: 364
    • 19c Figuero a Villar JD. Vieira A. Marinho B. Souza L. Fernandes P. Med. Chem. Commun. 2015; 6: 1427
      Crossref
    • 20a Ramachary DB. Kishor M. Ramakumar K. Tetrahedron Lett. 2006; 47: 651
      Crossref
    • 20b Ramachary DB. Kishor M. Reddy YV. Eur. J. Org. Chem. 2008; 975
  • 21 Baruah B. Naidu PS. Borah P. Bhuyan PJ. Mol Diversity 2012; 16: 291
    CrossrefPubMed
  • 22 Ramachary DB. Reddy GB. Org. Biomol. Chem. 2006; 4: 4463
    CrossrefPubMed
  • 23 Fillion E. Kavoosi A. Nguyen K. Ieritano C. Chem. Commun. 2016; 52: 12813
    CrossrefPubMed
  • 24 General Procedure for the Synthesis of 5-Monoalkylbarbiturates 4aa–cp A mixture of barbituric acid 1 (1 mmol) and aldehyde 2 (1 mmol) was refluxed in 5 mL of water for an appropriate time until the generation of 5-arylidenebarbituric acid as indicated by TLC. Next 2-aminothiophenol (3, 1 mmol) and benzaldehyde (2a, 1 mmol) were added, and the reaction mixture was further refluxed for an appropriate time. On completion of the reaction as indicated by TLC the reaction mixture was allowed to cool to room temperature and was extracted with EtOAc (3 × 10 mL). After drying with anhydrous Na2SO4 and evaporation under reduced pressure, the crude product was purified suitably either by recrystallization from a DCM/EtOH (1:1) solvent mixture or column chromatography on silica gel using EtOAc/hexane (2:8) as the eluent to afford 5-monoalkylbarbiturate 4. 5-Benzylpyrimidine-2,4,6(1H,3H,5H)-trione (4aa) White solid; 0.191 g (88%); mp 209–210 °C. 1H NMR (300 MHz, DMSO-d 6): δ = 3.22–3.24 (m, 2 H), 3.87–3.90 (m, 1 H), 7.05–7.24 (m, 5 H), 11.17 (s, 2 H) ppm. 13C NMR (75 MHz, DMSO-d 6): δ = 33.3, 49.3, 126.7, 128.3, 128.9, 137.4, 150.6, 170.0 ppm. IR (KBr): νmax = 3234, 2939, 1716, 1681, 1581 cm–1. ESI-MS: m/z calcd for C11H10N2O3 +: 218.07; found: 219.0 [M + H]+. Anal. Calcd (%) for C11H10N2O3: C, 60.55; H, 4.62; N, 12.84. Found: C, 60.70; H, 4.46; N, 13.02. 5-Cinnamyl-6-hydroxypyrimidine-2,4(1H,3H)-dione (4ah) Pale yellow sticky solid; 0.195 g (80%). 1H NMR (300 MHz, DMSO-d 6): δ = 2.68 (d, 2 H, J = 7.2 Hz), 5.99–6.09 (m, 1 H), 6.27 (s, 1 H), 6.41 (d, 1 H, J = 15.9 Hz), 7.19–7.31 (m, 5 H), 11.28 (s, 2 H) ppm. 13C NMR (75 MHz, DMSO-d 6): δ = 43.0, 75.0, 121.5, 126.2, 127.7, 128.4, 128.7, 134.3, 136.5, 150.0, 171.6 ppm. IR (KBr): νmax = 3234, 3030, 2974, 1734, 1680, 1616, 1560 cm–1. ESI-MS: m/z calcd for C13H12N2O3 +: 244.08; found: 245.0 [M + H]+. Anal. Calcd (%) for C13H12N2O3: C, 63.93; H, 4.95; N, 11.47. Found: C, 64.08; H, 5.07; 11.29. 1,3-Dimethyl-5-(thiophen-2-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione (4cn) Pale yellow solid; 0.226 g (90%); mp 118–119 °C. 1H NMR (300 MHz, CDCl3): δ = 3.20 (s, 6 H), 3.72 (s, 3 H), 6.76–6.77 (m, 1 H), 6.85–6.88 (m, 1 H), 7.12–7.13 (m, 1 H) ppm. 13C NMR (75 MHz, CDCl3): δ = 28.4, 30.7, 50.4, 125.2, 127.0, 127.2, 136.4, 151.0, 167.7 ppm. IR (KBr): νmax = 2976, 1672, 1589 cm–1. ESI-MS: m/z calcd for C11H12N2O3S+: 252.06; found: 253.0 [M + H]+. Anal. Calcd (%) for C11H12N2O3S: C, 52.37; H, 4.79; N, 11.10. Found: C, 52.22; H, 4.94; 10.98. 1,3-Dimethyl-5-(naphthalen-1-ylmethyl)pyrimidine-2,4,6(1H,3H,5H)-trione (4cp) White solid; 0.266 g (90%); mp 153–154 °C. 1H NMR (300 MHz, CDCl3): δ = 2.92 (s, 6 H), 3.91 (s, 3 H), 7.22 (t, 1 H, J = 6.9 Hz), 7.33 (t, 1 H, J = 7.8 Hz), 7.47–7.53 (m, 2 H), 7.75 (d, 1 H, J = 8.4 Hz), 7.82 (d, 1 H, J = 8.1 Hz), 7.94 (d, 1 H, J = 8.4 Hz) ppm. 13C NMR (75 MHz, CDCl3): δ = 28.1, 34.7, 50.8, 123.2, 124.9, 125.8, 126.3, 127.7, 128.6, 128.9, 131.4, 131.5, 133.7, 150.9, 168.6 ppm. IR (KBr): νmax = 3953, 1695, 1658, 1560 cm–1. ESI-MS: m/z calcd for C17H16N2O3 +: 296.12; found: 297.1 [M + H]+. Anal. Calcd (%) for C17H16N2O3: C, 68.91; H, 5.44; N, 9.45. Found: C, 68.76; H, 5.60; N, 9.63.
    • 25a Kalita SJ. Mecadon H. Deka DC. RSC Adv. 2014; 4: 10402
      Crossref
    • 25b Kalita SJ. Mecadon H. Deka DC. RSC Adv. 2014; 4: 32207
      Crossref
    • 25c Kalita SJ. Mecadon H. Deka DC. Tetrahedron Lett. 2015; 56: 731
      Crossref
    • 25d Kalita SJ. Saikia N. Deka DC. Mecadon H. Res. Chem. Intermed. 2016; 42: 6863
      Crossref
    • 25e Kalita SJ. Deka DC. Mecadon H. RSC Adv. 2016; 6: 91320
      Crossref
    • 25f Kalita SJ. Bayan R. Devi J. Brahma S. Mecadon H. Deka DC. Tetrahedron Lett. 2017; 58: 566
      Crossref
    • 25g Kalita SJ. Das B. Deka DC. SynOpen 2017; 1: 45
      Article in Thieme Connect
    • 25h Kalita SJ. Das B. Deka DC. ChemistrySelect 2017; 2: 5701
      Crossref
  • 26 Chikashita H. Miyazaki M. Itoh K. Synthesis 1984; 308
    Article in Thieme Connect
  • 27 Zhu C. Akiyama T. Org. Lett. 2009; 11: 4180
    CrossrefPubMed
    • 28a Fringuelli F. Piermatti O. Pizzo F. Vaccaro L. Eur. J. Org. Chem. 2001; 439
    • 28b Butler RN. Cunningham WJ. Coyne AG. Burke LA. J. Am. Chem. Soc. 2004; 126: 11923
      Crossref
    • 28c Chanda A. Fokin VV. Chem. Rev. 2009; 109: 725
      Crossref
    • 28d Simon M.-O. Li C.-J. Chem. Soc. Rev. 2012; 41: 1415
      Crossref
    • 28e Osuna S. Kim S. Bollot G. Houk KN. Eur. J. Org. Chem. 2013; 2823
    • 28f Norcott P. McErlean CS. P. Org. Biomol. Chem. 2015; 13: 6866
      CrossrefPubMed
    • 28g Ayub K. Ludwig R. RSC Adv. 2016; 6: 23448
      Crossref
    • 28h Chougala BM. Samundeeswari S. Holiyachi M. Shastri LA. ChemistrySelect 2017; 2: 1290
      Crossref
  • 29 CCDC 1574477 contains the supplementary crystallographic data for compound 4cn. The data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/getstructures.